Description

Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity[1].–80°C, protect from light-Applications-Cancer-programmed cell death-Formula-N/A-Citation–References-[1]Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.-CASNumber-2238831-60-0-MolecularWeight-149000 (average)-Compound Purity-99.54-SMILES-[Datopotamab deruxtecan]-Research_Area-Cancer-Solubility-10 mM in DMSO-Target-Antibody-Drug Conjugates (ADCs);Topoisomerase;TROP2-Isoform-Topo I-Pathway-Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Immunology/Inflammation-MCE Product type-ADC Related